Skip to content

Comparison of the effects of sufentanil and teligidine in patient-controlled intravenous analgesia after gynecological transumbilical single-port laparoscopic surgery

Comparison of the effects of sufentanil and teligidine in patient-controlled intravenous analgesia after gynecological transumbilical single-port laparoscopic surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500101889
Enrollment
Unknown
Registered
2025-04-30
Start date
2025-05-05
Completion date
Unknown
Last updated
2025-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative analgesia

Interventions

Experimental group:According to the data provided in the product manual of Tygilidine Fumarate Injection, the postoperative analgesic administration method of Tygilidine Fumarate was a loading dose of
Control group:The loading dose of sufentanil group was 3ug, the .9% normal saline configuration was 1ug/ml and 3 mg glastron, the background dose was 1ml/h, the single compression dose was 1ml, and th

Sponsors

Sichuan Provincial Maternal and Child Health Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients who are scheduled for gynecological transumbilical single-port laparoscopic surgery under general anesthesia and will undergo postoperative PCIA. 2. Age > 18 years. 3. Body mass index (BMI) 18.5–30kg/m^2. 4. ASA LEVELS I–III. 5. Voluntarily participate and provide written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with severe cardiocerebropathy, liver and kidney diseases; 2. Those who suffer from psychiatric diseases (schizophrenia, mania, bipolar abnormalities, mental confusion, etc.) and a history of long-term use of psychotropic drugs, have cognitive dysfunction, and are unable to communicate normally; 3. Those who are allergic to or contraindicated to benzodiazepines, opioids, propofol, muscle relaxants and other drugs and their drug components; 4. Those who plan not to remove the endotracheal tube after surgery. 5. Participated in drug clinical trials as a subject in the past 3 months; 6. Pregnancy or lactation 7. Other conditions that the investigator considers inappropriate to participate in this trial. 8. History of opioid use within eight weeks of surgery.

Design outcomes

Primary

MeasureTime frame
Resting VAS score at 3h, 24h, and 48h after surgery;

Secondary

MeasureTime frame
Rescue medication situation in the operating room;Time to extubation after surgery;PCA self-controlled analgesia, actual number of compressions and effective number of compressions;Residual drug in postoperative PCIA;Visual analogue score (VAS score) at 3 h, 24 h, and 48 h postoperatively;FAS assessment scale score;QoR-15 Recovery Quality Score;Level of sedation (Ramsay Sedation Scoring Criteria);Side effects (nausea, vomiting, dizziness, itching, respiratory depression, etc.) and intestinal recovery time;First eating and first exercise;Patient satisfaction;

Countries

China

Contacts

Public ContactChen Benzhen/Cui Chang

Sichuan Provincial Maternal and Child Health Hospital

326142589@qq.com+86 135 6827 5770

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026